
## Sung-Hee Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7586096/publications.pdf Version: 2024-02-01



SUNC-HEELIM

#	Article	IF	CITATIONS
1	Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. Korean Journal of Internal Medicine, 2021, 36, S217-S224.	1.7	6
2	TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. Current Issues in Molecular Biology, 2021, 43, 917-931.	2.4	5
3	Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Yonsei Medical Journal, 2021, 62, 671.	2.2	4
4	Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine. Vaccines, 2021, 9, 1379.	4.4	12
5	Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Journal of Clinical Oncology, 2020, 38, 488-495.	1.6	233
6	ls immunological recovery clinically relevant at 100 days after allogeneic transplantation?. Korean Journal of Internal Medicine, 2020, 35, 957-969.	1.7	3
7	microRNA-22 and TET-2 Mutation in Myelodysplastic Syndrome Patients Treated with Hypomethylating Agents. Blood, 2018, 132, 5127-5127.	1.4	0
8	Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. European Journal of Cancer, 2016, 52, 1-9.	2.8	115